Drug Safety Alert: IPC flags adverse reactions linked to Ibuprofen
New Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of January, has revealed that Ibuprofen is associated with Adverse Drug Reactions (ADRs) named Fixed Drug Eruption.
This came after preliminary analysis of Adverse Drug Reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. It it is a non-selective inhibitor of cyclooxygenase, which is an enzyme involved in prostaglandin (mediators of pain and fever) and thromboxane (stimulators of blood clotting) synthesis via the arachidonic acid pathway. Ibuprofen is very common over the counter medication widely used as an analgesic, anti-inflammatory and antipyretic. It is indicated for the treatment of chronic arthritic disorders and painful musculoskeletal conditions.
Following the preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database, it is reported that Ibuprofen can lead to Adverse Drug Reactions (ADRs) known as Fixed Drug Eruption.
A fixed-drug eruption (FDE) is a unique cutaneous adverse drug effect in the form of recurrent lesions at the same site after re-exposure to the offending agent.
Now, as per the issued drug safety alert, the following suspected drug is associated with the ADRs as given below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.